Avian Influenza A Hemagglutinin Antibody (8J159)

Product Discontinued

Avian Influenza A Hemagglutinin Antibody (8J159) Summary

• Immunogen: Hybidoma from Sp2/0 myeloma cells with spleen cells from Balb/c mice immunized with purified Avian Influenza Virus Type A (H5N1).
• Isotype: IgG2a
• Clonality: Monoclonal
• Host: Mouse
• Purity: Protein G purified

Applications/Dilutions

• Dilutions:
  • Dot Blot 1:100-1:2000
  • ELISA 1:100-1:2000
  • Haemagglutination
• Application Notes: .

Packaging, Storage & Formulations

• Storage: Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.
• Buffer: PBS (pH 7.4)
• Preservative: 0.1% Sodium Azide
• Purity: Protein G purified

Alternate Names for Avian Influenza A Hemagglutinin Antibody (8J159)

• ha; HA1; HA2; Hemagglutinin; Hemagglutinin ha1 chain; Hemagglutinin ha2 chain; Hemagglutinin precursor

Background

Influenza A virus is a major public health threat, killing more than 30,000 people per year in the USA. Novel influenza virus strains caused by genetic drift and viral recombination to which humans have little or no immunity, emerge periodically, resulting in devastating pandemics. Influenza A can exist in a variety of animals; however it is in birds that all subtypes can be found. These subtypes are classified based on the combination of the virus coat glycoproteins hemagglutinin (HA) and neuraminidase (NA) subtypes. During 1997, an H5N1 avian influenza virus was determined to be the cause of death in 6 of 18 infected patients in Hong Kong. There was some evidence of human to human spread of this virus, but it is thought that the transmission efficiency was fairly low. HA interacts with cell surface proteins containing oligosaccharides with terminal sialyl residues. Virus isolated from a human infected with the H5N1 strain in 1997 could bind to oligosaccharides from human as well as avian sources, indicating its species-jumping ability.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.